. [J]. Asian Journal of Urology, 2021, 8(2): 248-250.
Sophie Knipper,Gunhild von Amsberg,Franziska Stolzenbach,Thomas Steuber,Matthias Heck,Matthias Eiber,Christoph Berliner,Tobias Maurer. Multimodal therapy in oligometastatic prostate cancer: A glimpse into the future?. Asian Journal of Urology, 2021, 8(2): 248-250.
Perera M, Papa N, Roberts M, Williams M, Udovicich C, Vela I, et al. Gallium-68 prostate-specific membrane antigen positron emission tomography in advanced prostate cancerdUpdated diagnostic utility, sensitivity, specificity, and distribution of prostate-specific membrane antigen-avid lesions: a systematic review and meta-analysis. Eur Urol 2019; 77:403e17.
[2]
Maurer T, Eiber M, Schwaiger M, Gschwend JE. Current use of PSMA-PET in prostate cancer management. Nat Rev Urol 2016; 13:226e35.
[3]
Han S, Woo S, Kim YJ, Suh CH. Impact of 68Ga-PSMA PET on the management of patients with prostate cancer: a systematic review and meta-analysis. Eur Urol 2018; 74:179e90.
[4]
James ND, Sydes MR, Clarke NW, Mason MD, Dearnaley DP, Spears MR, et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm,multistage, platform randomised controlled trial. Lancet Lond Engl 2016 19;387:1163e77.
[5]
Maurer T, Robu S, Schottelius M, Schwamborn K, Rauscher I, van den Berg NS, et al. 99mTechnetium-based Prostate-specific membrane antigen-radioguided surgery in recurrent prostate cancer. Eur Urol 2019; 75:659e66.
[6]
Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY, et al. Abiraterone plus prednisone in metastatic,castration-sensitive prostate cancer. N Engl J Med 2017; 377:352e60.
[7]
Smith MR, Saad F, Chowdhury S, Oudard S, Hadaschik BA, Graff JN, et al. Apalutamide treatment and metastasis-free survival in prostate cancer. N Engl J Med 2018; 378:1408e18.
[8]
Chi KN, Agarwal N, Bjartell A, Chung BH, Pereira de Santana GomesAJ, Given R, et al. Apalutamide formetastatic, castrationsensitive prostate cancer. N Engl J Med 2019; 381:13e24.
[9]
Parker CC, James ND, Brawley CD, Clarke NW, Hoyle AP, Ali A, et al. Radiotherapy to the primary tumour for newly diagnosed,metastatic prostate cancer (STAMPEDE): a randomized controlled phase 3 trial. Lancet Lond Engl 2018; 392:2353e66.
[10]
Heidenreich A, Pfister D, Porres D. Cytoreductive radical prostatectomy in patients with prostate cancer and low volume skeletal metastases: results of a feasibility and casecontrol study. J Urol 2015; 193:832e8.
[11]
Sooriakumaran P, Karnes J, Stief C, Copsey B, Montorsi F, Hammerer P, et al. A multi-institutional analysis of perioperative outcomes in 106 men who underwent radical prostatectomy for distant metastatic prostate cancer at presentation. Eur Urol 2016; 69:788e94.
[12]
Horn T, Kr?nke M, Rauscher I, Haller B, Robu S, Wester HJ, et al. Single lesion on prostate-specific membrane antigenligand positron emission tomography and low prostatespecific antigen are prognostic factors for a favorable biochemical response to prostate-specific membrane antigentargeted radioguided surgery in recurrent prostate cancer. Eur Urol 2019; 76:517e23.
[13]
Ost P, Reynders D, Decaestecker K, Fonteyne V, Lumen N, De Bruycker A, et al. Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective,randomized, multicenter phase II trial. J Clin Oncol Off J Am Soc Clin Oncol 2018; 36:446e53.
[14]
Siva S, Bressel M, Murphy DG, Shaw M, Chander S, Violet J, et al. Stereotactic abative body radiotherapy (SABR) for oligometastatic prostate cancer: a prospective clinical trial. Eur Urol 2018; 74:455e62.
[15]
Bowden P, See AW, Frydenberg M, Haxhimolla H, Costello AJ, Moon D, et al. Fractionated stereotactic body radiotherapy for up to five prostate cancer oligometastases: Interim outcomes of a prospective clinical trial. Int J Canc 2020; 146:161e8.
